For some older adults, the flu vaccine could look a little different this year. In August, the US Food and Drug Administration approved the nation’s first mRNA-based flu vaccine for use in people 50 ...

The results, which triggered Moderna’s stock to drop, are “really encouraging,” says Karen Knudsen, CEO of the Parker ...

When the news arrived in August that what could be the first personalized mRNA cancer vaccine had succeeded in a late-stage ...

Moderna and Merck are preparing to seek regulatory approval after their experimental melanoma vaccine delivered promising ...

The conversation has already turned to how melanoma specialists should adopt the medicine — and how widely these novel vaccines can be deployed.

Severe sunburn increases the risk of developing melanoma, the most serious type of skin cancer. Credit: Olga Pankova/Getty. A ...

The FDA approved Moderna's mFlusiva in August, and it's now available to adults 50 and older.

Skepticism about the government’s pandemic response is one thing. Writing off mRNA vaccine technology is another.

A needle-free vaccination method protected mice against the viruses that cause COVID-19 and flu, offering a possible new way ...

Moderna’s stock has taken a big hit that might signal the end of this year’s cancer vaccine-driven rally. It may not, however ...